Drug Approval | March 25, 2022
USFDA approves Janssen’s injectable regimen for HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Routine tests undertaken by women dropped by 35% in 2020
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Recall does not include any metabolic deficiency nutrition formulas
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Subscribe To Our Newsletter & Stay Updated
